BRAF and melanoma: Furthermore, our findings unveil a previously unrecognized role of the HDAC10-SPARC axis in modulating BRAFi response in BRAF mutant melanoma cells; HDAC10 depletion significantly re-sensitizes PLX4032-resistant melanoma cells to PLX4032 treatment, while SPARC depletion partially reverses this effect.